AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT02474199
Drug: Acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pre-medication for darTregs infusion. A dose of 15 mg/kg will be administered 30 to 60 minutes prior to the darTregs infusion.
Trial: NCT01026870
Drug: Placebo metered-dose inhaler BID
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 inhalations from a placebo metered-dose inhaler each morning and evening, approximately 12 hours apart, for 12 weeks.
Trial: NCT04586803
Drug: SHR4640
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects were randomly divided into the group A, B, C, D, E and F. On D1, D8 and D15, six groups of subjects were respectively given A version or C version or D version of SHR4640 tablet.
Trial: NCT01489046
Drug: Placebo matching with BMS-986001
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsules, Oral, 0 mg, Once daily, At least 48 weeks
Trial: NCT02135224
Drug: Fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02135224
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02619409
Drug: EPI25
RxNorm normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The EPI25 group will receive bupivacaine 0.5% 3cc, epinephrine 1:1000 0.025cc, and sterile saline 0.075cc.
Trial: NCT02619409
Drug: EPI50 group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The EPI50 group will receive bupivacaine 0.5% 3cc, epinephrine 1:1000 0.05cc, and sterile saline 0.05cc
Trial: NCT02619409
Drug: EPI75 group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The EPI75 group will receive bupivacaine 0.5% 3cc, epinephrine 1:1000 0.075cc, and sterile saline 0.025%.
Trial: NCT02619409
Drug: EPI100 group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The EPI100 group will receive bupivacaine 0.5% 3cc, and epinephrine 1:1000 0.1cc.
Trial: NCT01714310
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Initiated at end of study week 4 and continued to study week 12.
Trial: NCT01714310
Drug: fluoxetine
RxNorm normalized name: Fluoxetine
DrugBank: Fluoxetine (DB00472)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Initiated at end of study week 4 and continued to study week 12.
Trial: NCT02822508
Drug: BLI801 Laxative
RxNorm normalized name: LAXATIVES
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BLI801 oral laxative
Trial: NCT02822508
Drug: BLI801 Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BLI801 oral laxative placebo
Trial: NCT00994448
Drug: Placebo tablets
RxNorm normalized name: placebo Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One placebo tablet twice daily
Trial: NCT03670810
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally.
Trial: NCT01474642
Drug: Capecitabine/Cisplatin(XP)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capecitabine/Cisplatin(XP) D1-D14 Capecitabine 2000mg/m2 D#2 PO D1 Cisplatin 75mg/m2 iv q 3 weeks
Trial: NCT01474642
Drug: Capecitabine/Paditaxel(XG)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capecitabine/Paditaxel(XG) D1-D14 Capecitabine 2000mg/m2 D#2 PO D1,D8 Paditaxel(genexol) 80mg/m2 iv q 3 weeks
Trial: NCT01471548
Drug: TKI258
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04155515
Drug: TG-2349
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TG-2349 400mg
Trial: NCT04155515
Drug: DAG181
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DAG181 200mg
Trial: NCT00004903
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT04156815
Drug: Oral isotretinoin
RxNorm normalized name: Isotretinoin
DrugBank: Isotretinoin (DB00982)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral isotretinoin has remained the most effective medication for moderate-to-severe AV.Subjects received oral isotretinoin (Xingyi Yan'an Pharmaceutical, Shanghai, China) (1mg/kg/d for the first 2-4 weeks and 0.5mg/kg/d for the next 12-14 weeks) for a total of 16 weeks. Serum triglycerides, cholesterol and levels of liver enzymes were monitored every month during oral isotretinoin medication.
Trial: NCT04339400
Drug: TQ05105
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TQ05105 is a JAK2 inhibitor.
Trial: NCT04183556
Drug: Naproxen
RxNorm normalized name: Naproxen
DrugBank: Naproxen (DB00788)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: use of naproxen twice a day orally in mens time
Trial: NCT02815748
Drug: SP2086
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SP2086 was taken only one time at 100mg dose in health volunteers
Trial: NCT02089061
Drug: Rosuvastatin
RxNorm normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02153944
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo was given orally during study visit
Trial: NCT00807534
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo nebulization
Trial: NCT00446719
Drug: Rellidep
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2000 mg P.O. daily for 8 weeks
Trial: NCT01091571
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo twice daily during seven consecutive days
Trial: NCT03077503
Drug: Fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Fentanyl 1 µg/kg diluted to 2 ml with 0.9% normal saline was administration. If adverse events were occurred, the patient will receive rescue drugs.
Trial: NCT03077503
Drug: 0.9% normal saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.9% normal saline was use to dilute the study drugs
Trial: NCT02340234
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo matching to lebrikizumab will be administered as per the schedule specified in the respective arms.
Trial: NCT04619056
Drug: CEB-01 membrane loaded with SN-38
RxNorm normalized name: sn-3-GPC
DrugBank: Choline alfoscerate (DB04660)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CEB-01 is a polymeric drug with a delivery system loaded with SN-38, and will be placed in the surgical bed at the time of tumor resection.
Trial: NCT00499603
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 500 mg/m\^2 by vein on day 1 every 3 weeks (+/- 7 days) for 4 cycles.
Trial: NCT00499603
Drug: RAD001
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg by mouth weekly on Days 1, 8, \& 15 for 12 cycles.
Trial: NCT04036656
Drug: SYHA136 0.5 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral tablet
Trial: NCT04036656
Drug: SYHA136 1 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral tablet
Trial: NCT04036656
Drug: SYHA136 2.5 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral tablet
Trial: NCT04036656
Drug: SYHA136 5 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral tablet
Trial: NCT04036656
Drug: SYHA136 10 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral tablet
Trial: NCT04036656
Drug: SYHA136 20 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral tablet
Trial: NCT04036656
Drug: SYHA136 35 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral tablet
Trial: NCT04036656
Drug: SYHA136 50 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral tablet
Trial: NCT04036656
Drug: Placebo matching SYHA136 0.5 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral tablet
Trial: NCT04036656
Drug: Placebo matching SYHA136 1 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral tablet
Trial: NCT04036656
Drug: Placebo matching SYHA136 2.5 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral tablet
Trial: NCT04036656
Drug: Placebo matching SYHA136 5 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral tablet
Trial: NCT04036656
Drug: Placebo matching SYHA136 10 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral tablet
Trial: NCT04036656
Drug: Placebo matching SYHA136 20 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral tablet
Trial: NCT04036656
Drug: Placebo matching SYHA136 35 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral tablet
Trial: NCT04036656
Drug: Placebo matching SYHA136 50 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral tablet
Trial: NCT01639040
Drug: Placebo (for Dupilumab)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (for Dupilumab) once weekly (QW) for 4 weeks
Trial: NCT03950518
Drug: Arginine hydrochloride
RxNorm normalized name: Arginine Hydrochloride
DrugBank: Arginine (DB00125)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: AHC,12mg/d AH,40g/d
Trial: NCT01274624
Drug: Leucovorin
RxNorm normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 2-hour infusion of 400 mg/m2 on Day 1 every 2 weeks.
Trial: NCT01274624
Drug: Fluorouracil (5-FU)
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 400 mg/m2 intravenous bolus followed by 2400 mg/m2 as a continuous intravenous infusion over 46 hours administered on Day 1 every 2 weeks.
Trial: NCT01619033
Drug: BF2.649
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single dose 20 mg
Trial: NCT01505127
Drug: Clarithromycin
RxNorm normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04464681
Drug: M201-A Injection
RxNorm normalized name: OCTINOXATE 2.45 g in 35 g / TITANIUM DIOXIDE 4.03 g in 35 g / ZINC OXIDE 1.72 g in 35 g / OCTISALATE 1.58 g in 35 g TOPICAL CREAM [15HR COVER LASTING M201 Medium Beige SPF50]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active Substance: M201-A Route of administration: continuous intravenous injection
Trial: NCT04464681
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo: M201-A Placebo Route of administration: continuous intravenous injection
Trial: NCT01465646
Drug: levothyroxine
RxNorm normalized name: Levothyroxine
DrugBank: Levothyroxine (DB00451)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01327352
Drug: Oshadi D
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral administration
Trial: NCT00400647
Drug: Enteric-coated Mycophenolate sodium (EC-MPS)
RxNorm normalized name: mycophenolic acid
DrugBank: Mycophenolic acid (DB01024)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04209179
Drug: PCO371
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PCO371 capsule
Trial: NCT04209179
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsule
Trial: NCT02180334
Drug: Acetaminophen (paracetamol)
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: On the day of MMTT, 3 tablets (1500 mg) of acetaminophen (paracetamol) will be administered orally to participants of both arms at the start of MMTT with manufactured mixed meal (0 min).
Trial: NCT01554618
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT01102413
Drug: Iron Sulphate
DrugBank: Iron (DB01592)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral intake
Trial: NCT01514695
Drug: Fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 100mcg intravenously given in 2mL syringe at start of procedure
Trial: NCT00477672
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tablet, once daily by mouth, 6 weeks
Trial: NCT01455012
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching Placebo. Subjects will be titrated to their optimal/maximal dose in weekly increments of 1 mg/24 h during a Titration Period. During Maintenance Period the subjects will continue on their optimal/maximal dose for 28 days. Following the Maintenance Period, subjects will be de-escalated over 7 days, depending on their optimal/maximal dose.
Trial: NCT04657497
Drug: FOY-305
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Specified Dosage and Duration of Treatment
Trial: NCT04657497
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Specified Dosage and Duration of Treatment
Trial: NCT03041012
Drug: 3BNC117
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg/kg 3BNC117 will be administered IV on day 7 and 21 after initiating ART
Trial: NCT03041012
Drug: Antiretrovirals
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination antiretroviral therapy
Trial: NCT04074317
Drug: Regular Insulin
RxNorm normalized name: Regular insulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SC injection
Trial: NCT00373516
Drug: Vehicle (Placebo) applied BID
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00373516
Drug: QRX-101 75 mcg/g ointment applied QD
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00373516
Drug: QRX-101 75 mcg/g ointment applied BID
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00403273
Drug: Normal Saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single Intra-articular Injection of 5 cc of normal saline in the Painful TKA at screening visit
Trial: NCT00160316
Drug: 0.5 Mg Estradiol and 2.5 Mg Dydrogesterone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: p.o. daily
Trial: NCT00610532
Drug: phenytoin
RxNorm normalized name: Phenytoin
DrugBank: Phenytoin (DB00252)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: intravenous phenytoin (15 mg/kg) single dose
Trial: NCT00610532
Drug: phenytoin and probenecid
RxNorm normalized name: colchicine and probenecid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intravenous phenytoin (15 mg/kg) single dose and oral probenecid 2000 mg single dose
Trial: NCT00849368
Drug: Azathioprine / Allopurinol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both drugs are applied orally. A pre-specified dose escalation regimen will be chosen.~Azathioprine: Imurek (R) 50 mg and 25 mg tablets~Allopurinol: Mephanol (R) 100 mg tablets
Trial: NCT04490434
Drug: DWP14012
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DWP14012 40mg, bid
Trial: NCT04490434
Drug: Celecoxib
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Celecoxib 200mg, bid
Trial: NCT04490434
Drug: Naproxen
RxNorm normalized name: Naproxen
DrugBank: Naproxen (DB00788)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Naproxen 500mg, bid
Trial: NCT04490434
Drug: Meloxicam
RxNorm normalized name: Meloxicam
DrugBank: Meloxicam (DB00814)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Meloxicam 15mg, qd
Trial: NCT02595736
Drug: Placebo (SC)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered SC
Trial: NCT02595736
Drug: LY3200327 (SC)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered SC
Trial: NCT02595736
Drug: LY3200327 (IV)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered IV
Trial: NCT02595736
Drug: Placebo (IV)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered IV
Trial: NCT04147312
Drug: Fufang E'Jiao Jiang
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fufang E'Jiao Jiang, 20milliliters(mL) once, 3 times a day, continuous intervention for 21 days each cycle, and use 2 cycles
Trial: NCT04147312
Drug: placebo containing low-dose fufang E'Jiao Jiang
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo containing low-dose Fufang E'Jiao Jiang, 20mL once, 3 times a day, continuous intervention for 21 days each cycle, and use 2 cycles
Trial: NCT02795390
Drug: Chinese herbal medicine
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02795390
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT05235191
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In this arm patients will take placebo tablets (the same number, color and physical aspects as the methadone tablets).
Trial: NCT01550419
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The smell and shape of placebo are the same as atorvastatin
Trial: NCT01945489
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline (placebo) injected into the detrusor.
Trial: NCT00829322
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One capsule daily for 14 days, increasing to two capsules daily for 14 days
Trial: NCT03509675
Drug: Ibuprofen suspension 5mg/100ml
RxNorm normalized name: ibuprofen Oral Suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-Steroidal Anti-inflammatory Topical Rinse will be used for Symptomatic OLP patients.
Trial: NCT03509675
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT01139281
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The subjects were randomized and allocated in two groups: control group and study group. The control group received placebo plus cisplatin and was guided to ingest Placebo just before initial cisplatin dosage. The maximum cumulative cisplatin dosage was 300mg/m². They were followed up for ninety days. Comparisons were made between baseline distortion-product otoacoustic emissions measurements and those DPOAE records after maximum cumulative cisplatin dosage.
Trial: NCT03323528
Drug: Benzalkonium Chloride-Benzocaine Topical
RxNorm normalized name: benzalkonium chloride-benzocaine topical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dorithricin = tyrothricin, benzalkonium chloride, benzocaine
Trial: NCT03323528
Drug: Placebo Oral Tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo Oral Tablet = a lozenge with matched appearance and the same excipients as Active Comparator Dorithricin lozenge.~Intervention: Patients are instructed to administer at home 1 lozenge at intervals of 2 hours (±15 minutes) up to a maximum of 8 lozenges per day.
Trial: NCT02980965
Drug: letrozole, leuprorelin, fluorouracil, epirubicin, cyclophosphamide, docetaxel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Postmenopausal patients were treated with letrozole 2.5mg/day p.o until complement of neoadjuvant chemotherapy before surgery, while premenopausal ones received letrozole 2.5mg/day p.o and a subcutaneous injection of the GnRH-a, leuprorelin, as concomitant treatment with neoadjuvant chemotherapy (fluorouracil 600mg/m2 IV, epirubicin 90mg/m2 IV and cyclophosphamide 600mg/m2 IV on day 1 at 3-weekly intervals for 3 cycles followed by docetaxel 100mg/m2 IV on day 1 at 3-weekly intervals for 3 cycles; or epirubicin 90mg/m2 IV and cyclophosphamide 600mg/m2 IV on day 1 at 2-weekly intervals for 4 cycles, followed by docetaxel 80mg/m2 IV on day 1 at 2-weekly intervals for 4 cycles), letrozole was delivered after 1 week of first dose of leuprorelin injection.
Trial: NCT02980965
Drug: fluorouracil, epirubicin, cyclophosphamide, docetaxel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients received fluorouracil 500mg/m2 IV, epirubicin 90mg/m2 IV and cyclophosphamide 500mg/m2 IV on day 1 at 3-weekly intervals for 3 cycles followed by docetaxel 100mg/m2 IV on day 1 at 3-weekly intervals for 3 cycles; or epirubicin 90mg/m2 IV and cyclophosphamide 600mg/m2 IV on day 1 at 2-weekly intervals for 4 cycles, followed by docetaxel 100mg/m2 IV on day 1 at 2-weekly intervals for 4 cycles.
Trial: NCT00275158
Drug: L-Arginine Supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04197570
Drug: Opioid Anesthetics
RxNorm normalized name: Opioid anesthetics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: see arm/group description
Trial: NCT04197570
Drug: Non Opioid Analgesics
RxNorm normalized name: Analgesic Balm GRX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: see arm/group description
Trial: NCT04476030
Drug: Matching Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral capsules
Trial: NCT04476030
Drug: Desvenlafaxine
RxNorm normalized name: Desvenlafaxine
DrugBank: Desvenlafaxine (DB06700)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral tablets
Trial: NCT00445510
Drug: GSK256066
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01963390
Drug: Testosterone Therapy
RxNorm normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: In this observational study we will be enrolling testosterone deficient men who intend to undergo testosterone therapy.
Trial: NCT02170584
Drug: BIBR 953 ZW IV
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02170584
Drug: BIBR 953 ZW IV Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04567316
Drug: [14C]-radiolabelled BI 1358894
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Part 1
Trial: NCT00934544
Drug: Best Available Therapy (BAT)
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prescribing and usage per respective package inserts
Trial: NCT01660711
Drug: 5 Fluorouracil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2400 mg/m2 by continuous intravenous infusion over 46 hours
Trial: NCT01660711
Drug: Leucovorin
RxNorm normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 400 mg/m2 by IV infusion over 2 hours
Trial: NCT01577238
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaginal gel, daily for 7 days